This is the March 18, 2019 announcement of funding for a PAH trial. There is a pilot study that was estimated for preliminary completion August 1, 2021 and estimated study completion Dec./21. I have added the bolding below for where the phase 2 trial is supposed to follow this pilot study which started August/2019. I remember it being mentioned that the PAH trial was either slowed or suspended due to COVID-19 so don’t know where it stands right now.

“CALGARY, Alberta, March 18, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the advancement of a $2.9 million project led by academic collaborators at Quebec Heart and Lung Institute, Laval University, to research the clinical potential of its lead drug apabetalone as a potential therapy for pulmonary arterial hypertension (“PAH”); key aspects of this phase 2 clinical study will be the assessment of safety and efficacy in this patient population.

The project has received prestigious funding by the Canadian Institutes of Health Research (“CIHR”), through an operating grant, and is matched by the Company including both in-kind and direct investment. The project is expected to initiate following completion of an already planned pilot study to begin in the first half of 2019.”